Grail CEO Bob Ragusa to Retire, Josh Ofman Succeeds Him

By Curie | Biotech Reporter

March 13, 2026 — Grail, the Bay Area-based cancer detection company, announced Thursday that Chief Executive Bob Ragusa will retire effective June 1, 2026, with company President Josh Ofman taking over as CEO.

The leadership change arrives just weeks after Grail disclosed disappointing results from a pivotal UK trial of its Galleri blood test, which failed to significantly reduce late-stage cancer diagnoses. The company's shares plummeted nearly 50% following the February announcement.

However, analysts said the timing is coincidental. "The CEO change has been in development for some time and is unrelated to the NHS trial readout," Guggenheim analyst Subbu Nambi told Reuters.

Ragusa, who became CEO in 2021, oversaw Grail's spinout from Illumina and the company's subsequent transition to an independent publicly traded company. He will remain on Grail's board through his retirement date and serve in an advisory capacity through March 2027.

Ofman, who joined Grail in 2019, previously spent more than 15 years at Amgen in senior roles focused on value, access, and health policy. He's been central to advancing Galleri's clinical and regulatory strategy.

"We are leading the multi-cancer early detection field with the most comprehensive body of evidence," Ofman said in a statement. "I am honored to step into this role at a time of strong momentum."

The Galleri test — which screens for traces of cancer DNA in the blood — is not yet FDA-approved. Grail sold 185,000 tests in 2025, generating $136.8 million in revenue, but the company remains unprofitable.

The NHS trial, involving over 140,000 UK residents aged 50-77, missed its primary endpoint of reducing Stage IV cancer diagnoses across all cancer types. The company said it plans to extend follow-up analysis by six months to a year.